Paper Details

  1. Home
  2. Paper Details

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.

Author: DingemansAnne-Marie C, DinhTrang, HendriksLizza E L, LaljiUlrich, SchieferMart

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-TKI, can cause QT prolongation. Discontinuation of osimertinib can lead to a symptomatic disease flare, presenting a difficult ethical dilemma for physicians.
Paper Details　
Original Abstract of the Article :
An increasing number of tyrosine kinase inhibitors (TKIs) are available for the treatment of non-small cell lung cancer (NSCLC). QT prolongation is one of the known, but relatively rare, adverse events of several TKIs (e.g. osimertinib, crizotinib, ceritinib). Screening for QT prolongation in (high ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2017.12.011

データ提供：米国国立医学図書館（NLM）

Monitoring the Shifting Sands of QT Prolongation

The world of cancer treatment is a vast and ever-changing desert, with new medications constantly emerging. This research focuses on osimertinib, a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC). While osimertinib offers hope in the battle against cancer, it can also present unexpected challenges, such as QT prolongation, a potentially serious side effect. This research explores the complexities of managing QT prolongation in patients receiving osimertinib, highlighting the importance of careful patient monitoring and balancing the risks and benefits of treatment.

Navigating the Risks and Benefits of Osimertinib

This research underscores the importance of careful patient monitoring when using osimertinib. While this medication holds significant potential for treating NSCLC, the risk of QT prolongation must be acknowledged and addressed. Healthcare providers need to be vigilant in screening for this side effect, particularly in high-risk patients, and carefully weigh the potential benefits of treatment against the risks associated with QT prolongation.

Implications for Lung Cancer Patients

For patients with NSCLC receiving osimertinib, this research emphasizes the importance of open communication with their healthcare providers. Regular monitoring of heart function and a thorough understanding of the potential risks and benefits of osimertinib are essential for making informed decisions about treatment. Patients should feel empowered to discuss any concerns or questions they may have, ensuring they receive the best possible care and support during their journey.

Dr. Camel's Conclusion

In the shifting sands of lung cancer treatment, osimertinib offers a beacon of hope, but careful navigation is crucial. Just as a desert traveler must be mindful of potential dangers, healthcare providers need to remain vigilant in monitoring for QT prolongation, ensuring patient safety while maximizing the benefits of this potentially life-saving medication.

Date :
  1. Date Completed 2018-10-23
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

29413968

DOI: Digital Object Identifier

10.1016/j.ejca.2017.12.011

Related Literature

Article Analysis
・Side Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.